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Standfirst 
Iron interventions are the mainstay of recommendations to combat the enormous 
global burden of anaemia; however recent scientific and epidemiologic insights 
suggest that in settings with high infection burden, this strategy is neither 
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satisfactorily safe nor effective and that to improve outcomes, control of infection 
must receive equal emphasis. 
 
Introduction 
Anaemia affects 273 million children and 529 million women globally,1 accounting for 
8.8% of all years lived with disability.2 Anaemia prevalence in children under-5 years 
is highest in sub-Saharan Africa (62.3%) and South-East Asia (53.8%),1 where rates 
of concomitant infection are also high. Between 1993-2011, the estimated anaemia 
prevalence worldwide only fell from 33% to 29% in non-pregnant women and from 
47% to 43% in pre-school children.3 The 2016 Global Nutrition Report found that 
progress towards the WHO target of 50% anaemia reduction in women by 2025 is 
100 years behind schedule.4  
 
Iron is an essential micronutrient required for many biological processes including 
oxygen transport, mitochondrial function, and numerous enzymatic pathways. Iron 
deficiency can therefore compromise diverse physiological functions and ultimately 
leads to anaemia. Public health strategies to control anaemia emphasise iron 
replenishment: food fortification with iron, universal distribution of iron supplements, 
and home-fortification of complementary foods with iron-containing multiple 
micronutrient powders (MNPs).5-7 Failures in resolving the anaemia burden have 
been attributed to programmatic limitations: problems with financing, supply, 
distribution or adherence to interventions.4 8 However, as discussed in this article, 
new understanding of iron-infection interactions, evidence from clinical trials, and 
anaemia epidemiology cast doubt into the safety and prominence of universal iron 
interventions as the mainstay of public health anaemia control, especially among 
young children in areas of high infectious burden. Although this has stimulated 
modifications to WHO iron intervention guidelines, a further change of approach to 
anaemia control is needed.  
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New insights into iron-infection interactions 
Anaemia control policy in children was upended in 2006 by a large trial in Pemba, 
Tanzania, that was prematurely terminated due to an increase in risk of death and 
hospitalisation, besides other serious infection related events, among children 
randomized to iron/folic-acid (Box 1). Although a parallel trial in (non-malaria-
endemic) Nepal did not detect these adverse effects, the Pemba study provoked 
urgent policy changes,9 reinvigorated clinical, epidemiologic and experimental 
research addressing iron-infection interactions, and coincided with rapid advances in 
fundamental understanding of iron biology. This work, which we describe below, 
highlights the importance of infection control in public health prevention and control 
of anaemia. 
 
1. Humans have evolved to withhold iron from the plasma during infection 
The discovery that hepcidin, the master iron-control hormone, is an inflammation-
regulated acute-phase peptide highlights the direct interaction between iron 
homeostasis and innate immunity.10 Hepcidin is secreted mainly by hepatocytes, 
causing internalization and degradation of the sole iron exporter ferroportin on 
macrophages and duodenal enterocytes, thereby preventing iron egress.11 Hepcidin 
upregulation during infection inhibits dietary iron absorption and macrophage release 
of recycled iron resulting in acute reductions in plasma iron levels; this impairs 
bacterial growth in plasma12 but simultaneously starves developing red cells of iron.  
 
At the high doses typical in supplements, oral iron can overwhelm natural hepcidin-
mediated constraints on iron absorption.13 Treating patients with iron supplements 
elevates transferrin saturation, providing a medium which enhances microbial growth 
(e.g. E coli, Yersinia, Salmonella) in ex vivo assays.14 Furthermore, iron deficient 
individuals more efficiently absorb iron supplements, resulting in a spike in plasma 
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iron that can temporarily overcome transferrin’s binding capacity, causing 
appearance of non-transferrin bound iron (NTBI)15 which enhances growth of virulent 
pathogens such as Yersinia and Vibrio species.16 Thus, at high doses, iron 
supplementation may promote pathogen growth by overcoming the hepcidin-
mediated iron-starvation response to inflammation.  
 
2. Iron deficiency protects children against malaria, and iron administration poses a 
transitory risk for malaria 
Cohort studies in Malawi and Tanzania showed that preschool children with baseline 
iron deficiency living where malaria transmission is intense and where no prophylaxis 
was distributed have a substantially reduced risk of subsequent malaria 
parasitaemia, clinical malaria, severe malaria, and all-cause and malaria-specific 
mortality.17 18  
 
Correspondingly, two iron intervention studies indicate that treating iron deficiency 
with iron increases malaria susceptibility. After receiving MNPs containing 18mg iron 
(with or without zinc), iron deficient Tanzanian children experienced a 41% increased 
malaria risk after receiving MNPs, while no increased risk was found among iron-
replete children.19 Likewise, increased malaria incidence was found in Malawian HIV-
infected anaemic children in the first three months following iron supplementation.20  
 
Although a 2016 Cochrane review found no overall effect of iron interventions on 
clinical malaria risk in children, subgroup analysis stratifying by malaria 
prevention/treatment access revealed that clinical malaria risk increased by 16% 
[2%-31%] when iron was administered without co-provision of prevention/treatment, 
but declined by 9% [16%-3%] when administered with control measures. 
Furthermore, iron increased Plasmodium parasitaemia risk by 11% [0%-23%] during 
supplementation, and by 23% [9-40%] in the post-supplementation period,21 
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supporting the cohort study findings described above. The consequent 2016 WHO 
guidelines therefore require that iron interventions only be given where strategies to 
prevent, diagnose and treat malaria are operational; however, malaria control in 
settings where iron interventions may be recommended is frequently suboptimal (see 
section 7).  
 
The above data are supported by experiments demonstrating preferential P. 
falciparum in vitro infection of erythrocytes from iron replete and recently iron-
supplemented donors, over those from iron deficient donors (with donors comprising 
healthy US adults22 and Gambian children receiving iron-containing MNPs.)23 
Merozoites preferentially invade young erythrocytes (reticulocytes), which increase 
during anaemia recovery following iron treatment, providing a mechanistic 
explanation for these observations.22 Another recent study observed protection from 
clinical malaria and parasitaemia in Ghanian pregnant women and Zambian children 
carrying the ferroportin Q248H mutation, shown previously to reduce ferroportin’s 
hepcidin sensitivity.24 Correspondingly, mice with erythoblast-specific ferroportin 
knockout were rendered susceptible to murine malaria, associated with increased 
red cell iron. 
 
Together, these data suggest a cruel paradox - whilst children with iron-deficiency 
anaemia are most likely to benefit from iron interventions, effective erythropoietic 
responses following iron places these same individuals at greatest risk through 
enhancing malaria susceptibility. Any solution that delivers iron for erythropoiesis and 
successfully restitutes anaemia by definition induces reticulocytosis, casting doubt 
that, in malarial settings, any effective iron intervention (supplement, fortificant, food) 
can be safe unless accompanied by reliable malaria prevention.  
 
3. Malaria is not the only infection exacerbated by iron interventions  
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In the colon, beneficial bacteria help prevent colonisation by pathogenic species and 
may not require iron (e.g. lactobacilli). In contrast, iron favours growth of enteric 
pathogens.25 Unabsorbed iron from supplements, MNPs and fortificants can 
exacerbate risk of intestinal colonisation by pathogenic species.26 Studies in non-
malaria-endemic settings in Pakistan found increased diarrhoea (including bloody-
diarrhoea) from iron-containing MNPs,27 besides increased rapid chest indrawing, 
raising concern iron may also exacerbate respiratory infection risk. Contrastingly, the 
large Nepal trial (Box 1) found no effects from supplemental iron on infections 
including diarrhoea.28 Nevertheless, systematic reviews published in 2016, 2013 and 
2002 (i.e. before these large trials) each found that iron interventions increased 
diarrhea risk ( by 15% [6-26%]21, 4% [1-6%]29 and 11% [1-23%]30 respectively). 
Studies evaluating how iron fortification influences intestinal microbiota provide a 
plausible mechanism underlying increased diarrhea following iron administration. 
Ivorian children given iron-fortified biscuits displayed reduced commensal lactobacilli, 
increased pathogenic enterobacteria and elevated intestinal inflammatory 
biomarkers.31 Likewise, increased carriage of intestinal pathogens including 
Escherichia, Shigella and Clostridium and intestinal inflammation was found in 
Kenyan infants receiving iron-containing MNPs.26 Such effects were not observed in 
South African children with low baseline prevalence of pathogenic bacteria, 
suggesting a harmful effect of iron on intestinal microbiota may manifest in settings 
where carriage of pathogenic species is already prevalent, perhaps relating to 
underlying water, sanitation and hygiene (WASH) conditions. These trials were not 
powered to discern effects on gastrointestinal illness.  
4. Control of malaria alone may decrease iron deficiency 
Symptomatic and asymptomatic malaria parasitaemia inhibits iron absorption via 
hepcidin upregulation. In Beninese women with asymptomatic P. falciparum 
infection, anti-malarial treatment increased mean dietary iron absorption from 10% to 
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18%.32 Complementing this, the prevalence of iron deficiency and iron deficiency 
anaemia was significantly higher at the end than at the start of malaria seasons in 
rural West and East African pre-school children, suggesting suppression of iron 
absorption by infection.33 Moreover, interruption of malaria transmission for 12 
months in rural Kenya reduced the prevalence in young children of iron deficiency 
from 35% to 26%, and anaemia from 54% to 32%.34  
 
Cochrane reviews indicate that malaria control can improve haemoglobin or reduce 
anaemia: for example intermittent preventive therapy (IPT) reduces moderate 
anaemia by about 40% in pregnant women35 and 29% in children;36 bednet use 
increased haematocrit by 1.5%;37 and indoor residual spraying improved 
haemoglobin by 0.85g/dL (based on a single trial).38 Thus, malaria control alone may 
alleviate iron deficiency and anaemia even without iron provision.  
 
5. Iron supplementation to pregnant women in malaria endemic areas is likely safe 
and improves child outcomes 
Two large trials have recently evaluated effects of antenatal iron supplementation on 
malaria risk during pregnancy. In Kenyan women, there was no evidence of 
increased clinical malaria, placental malaria or parasitaemia among women 
randomized to oral iron, even among women who received limited or no IPT.39. 
Importantly, iron yielded clear benefits to both mother and child increasing birth 
weight by 150g, lengthening gestation duration by 3.4 days and reducing risk of low 
birth weight and premature birth by 58% and 7% respectively. Benefits were 
enhanced among women with baseline iron deficiency. Similar benefits of iron have 
been identified previously,40 41 but this trial was one of the first to include women with 
anaemia, potentially explaining the large impact on birth outcomes. In a second 
recent placebo-controlled trial in non-iron deficient, non-anaemic, pregnant 
Tanzanian women, iron supplementation did not increase placental malaria, although 
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no benefit on birth weight or gestation duration was observed, perhaps reflecting 
higher baseline iron status in this study population.42 These trials indicate that 
antenatal iron supplementation is safe even where malaria is highly endemic and 
malaria control strategies incompletely implemented (perhaps due to more 
developed host-immunity and/or tolerance to pathogen load in adulthood),43 and 
have important benefits on maternal and neonatal health when iron deficiency is 
prevalent. Detailed investigations of potential risks from iron in pregnancy on other 
infections are still warranted. 
 
6. The proportion of anaemia that is iron-responsive is lower than previously 
estimated 
Previously, at least half of anaemia cases were attributed to iron deficiency and so 
potentially iron-responsive. Anaemia prevalence in preschool children is highest in 
Africa, the Eastern Mediterranean, and Asia, in these settings, WHO estimates that 
in preschool children only 32%, 38% and 41% of anaemia respectively (42% 
globally) is iron-responsive.1 These figures are higher among women.1 Thus, non-
iron-responsive anaemia is prevalent in young children in low-income, high-infection 
settings - both malaria-endemic and non-endemic. The population response to iron is 
likely determined by the proportion of individuals able to absorb and utilise iron for 
erythropoiesis. Physiologically, iron absorption/utilization is determined by hepcidin 
status: in a study of 1313 Gambian and Kenyan infants, we found that only 27% had 
hepcidin concentrations below the threshold permitting effective iron absorption and 
utilisation.44 
 
Causes of anaemia beyond iron deficiency in these settings may include anaemia of 
inflammation, malaria, and carrier-states for or clinically evident inherited red cell 
disorders (e.g. thalassaemia, sickle cell disease and G6PD deficiency).  
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Co-existent multiple micronutrient deficiencies (e.g. of other haematinic 
micronutrients or vitamin A) could impair the haemoglobin response to iron. Vitamin 
A deficiency may impair immune function, exacerbating infection risk, promoting 
inflammation and impairing iron utilisation. Studies testing effects of vitamin A 
supplementation (with or without iron) on anaemia have yielded mixed results.45 Data 
comparing MNPs to iron supplements alone in children are lacking although in 
pregnancy, a meta-analysis of four trials found no additional benefit from MNPs on 
anaemia compared with iron alone.46  
 
Environmental enteropathy (EE) is a subclinical malabsorptive condition highly 
prevalent among children in low income countries, attributed to recurrent infection 
and chronic malnutrition, and characterised by intestinal villous atrophy, impaired 
barrier function, and intestinal inflammation.47 The role of intestinal functional 
impairment on iron absorption remains unclear, and causal links between EE and 
iron deficiency or anaemia have not yet been defined; however, it remains plausible 
that failure of luminal absorptive function may render anaemia non-iron responsive.    
 
Diagnosis of anaemia aetiology remains challenging in resource poor settings: 
biomarkers for iron deficiency remain expensive and difficult to interpret with 
concurrent inflammation, while sophisticated red cell testing is difficult to implement 
routinely in the field. The epidemiology of these conditions should be considered 
when planning anaemia control programs, as treatment of non-iron deficiency 
anaemia with iron is at best ineffective, and in settings with high infection burden, 
may increase risk of harm.  
 
7. Implementation of malaria prevention is frequently inadequate for safe delivery of 
universal iron interventions 
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WHO guidelines currently recommend universal iron or MNPs where anaemia 
prevalence exceeds 20-40%, even in malaria-endemic areas, as long as 
interventions to ‘prevent, diagnose and treat’ malaria are also provided. The 
appropriate forms of malaria-control to accompany iron interventions are not defined. 
For example, insecticide treated bednets reduce the incidence of uncomplicated 
clinical malaria, but only by about 50%.37 A trial in Ghana where all participants used 
insecticide-treated bednets did not find increased malaria from iron-containing MNPs, 
but did find a 23% [2-49%] increase in hospitalization during (but not following) the 
intervention period, suggesting bednets do not prevent iron-induced increases in 
serious adverse events.48  
 
The coverage of malaria prevention, diagnosis and treatment measures remain 
inadequate in high-risk settings. The 2016 World Malaria Report indicated that only 
57% of at-risk sub-Saharan African populations slept under a bednet (prevention), 
56% of febrile children are taken to trained health care providers (diagnosis), and 
30% of children with evidence of P falciparum infection and a history of fever receive 
antimalarial drugs (treatment).49 Thus, under routine conditions, it is likely that fewer 
than half of children in malaria-endemic settings would be covered such that iron 
interventions could be deployed safely; unselected, ‘universal’ distribution is likely 
unsafe. Although malaria burden has progressively declined over the last two 
decades, the 2017 World Malaria Report suggests that gains have plateaued or are 
even being reversed.50  
 
The risk-benefit of iron interventions in infection-endemic regions must be 
considered 
An important consideration prior to iron distribution is whether reductions in anaemia 
prevalence per se, or benefits on functional health outcomes such as development 
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and growth in young children (that are not yet supported by high quality evidence 
from randomized controlled trials51 52) justify the increased risk of infections.  
 
Global burden of disease data indicate that in 2016, the Disability Adjusted Life 
Years attributable to diarrhoea, malaria and iron deficiency anaemia in 1-4 year-old 
children were 11.1 million, 27.3 million and 1.8 million respectively in sub-Saharan 
Africa, and 3.5 million, 1.0 million, and 2.4 million respectively in South Asia.53 If iron 
interventions exacerbate risk of infectious diseases (even whilst reducing anaemia) 
they may raise the overall burden of disease in these settings. In contrast, controlling 
malaria and diarrhoea decreases burden of these infections, and by suppressing 
inflammation and hepcidin, could simultaneously improve iron absorption and 
utilization and contribute to reducing anaemia burden. 
 
We make policy recommendations in Box 2, and propose critical research priorities in 
Box 3.    
 
Key messages 
 Universal iron interventions designed to alleviate anaemia in young children living 
in low income countries may exacerbate risk of infection, especially malaria and 
diarrhoea.  
 Iron interventions alone will not resolve the majority of the burden of anaemia in 
young children living in sub-Saharan Africa and Asia. To achieve anaemia control 
in high infection burden settings, addressing infection is at least as important as 
iron interventions. Strategies to control and prevent malaria (and other infections) 
may improve anaemia burden independently of iron interventions, and if 
combined with iron, may make iron interventions safer and more effective.  
 Iron intervention should be prioritised in pregnant women, where safety has been 
demonstrated and benefits on maternal and neonatal outcomes are clear.  
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Box 1: Iron-Malaria policy since Pemba 
The Pemba Trial (Tanzania) was powered to demonstrate a survival benefit in 
children receiving iron, randomising over 24000 children aged 6-36 months to 
placebo, iron folic acid (IFA), and IFA with zinc. The trial was stopped early because 
of an increase in death or hospital admission among children randomized to IFA 
(with or without zinc) (relative risk 1.12 [95% CI 1.02–1.23]). IFA also increased 
hospital admissions (RR 1.11 [1.01–1.23]), cerebral malaria (RR 1.22 [1.02–1.46]), 
and serious adverse events (RR 1.32 [1.10–1.59]), deaths (RR 1.61 [1.03–2.52]) and 
admissions to hospital (RR 1.28 [1.05-1.55]) due to non-malarial infections. A 
substudy of 2413 children found that infection from iron was only increased in 
children without elevated baseline zinc protoporphyrin.  
 
A similar trial evaluating IFA in children in a non-malaria endemic setting (Nepal) was 
published simultaneously. This trial was also designed to demonstrate benefit from 
iron on child survival, but was terminated prematurely once there was no possibility a 
beneficial effect would be detected. It found no effects from iron on infections 
including diarrhoea.28  
 
Following Pemba, WHO suspended its policy of universal iron for children in malaria 
endemic areas, instead recommending IFA only in anaemic children.9 In 2011, based 
on a Cochrane review, WHO published new recommendations for MNP 
implementation to children where the prevalence of anaemia is high, stating that in 
malaria endemic areas, MNPs should be provided only to children with access to 
malaria preventive and treatment services.5 Over the past decade there has been 
rapid scaling up of MNP programmes. In 2015, up to 50 million children received 
MNPs.  
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Updated 2016 WHO guidelines reintroduced daily iron supplementation as a second 
option (alongside MNPs) in children, and based on an updated Cochrane review,21 
reiterated that in malaria–endemic areas, iron provision to children “should be done 
in conjunction with public health measures to prevent, diagnose and treat malaria.” 
Guidelines further state that “provision of iron … should not be made to children who 
do not have access to malaria-prevention strategies (e.g. provision of insecticide-
treated bednets and vector-control programmes), prompt diagnosis of malaria illness, 
and treatment with effective antimalarial drug therapy.”7 
 
Box 2: Policy Recommendations 
 Reducing the burden of anaemia should be considered an important additional 
rationale for, and outcome of, programmes to control infectious diseases.  
 As recommended by WHO, iron interventions should be withheld from children in 
malaria-endemic settings unless malaria prevention is provided. We propose that 
this implies delivery of iron and effective malaria control interventions should 
have identical coverage – malaria prevention and iron interventions should 
converge at the level of the individual child. In settings of high infection intensity, 
more aggressive approaches (e.g. beyond bednets alone), such as combining 
iron interventions with use of malaria chemoprevention, should be explored.  
 When effective in raising haemoglobin, the risk of iron exacerbating malaria is 
likely highest in initially anaemic children. Therefore, when treating anaemic 
children with iron, they must receive specific attention to malaria prevention 
during recovery. 
 Iron supplementation appears unambiguously beneficial in pregnancy, and hence 
delivery of and adherence to iron should be prioritised in pregnant women in low 
income countries.  
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Box 3: Research needs   
 The optimal type of malaria prevention measures to be co-implemented with iron, 
that render iron interventions safe, should be defined in adequately powered 
prospective studies. The burden of malaria (e.g. clinical incidence, parasite 
prevalence, entomological inoculation rate) and coverage of effective malaria 
prevention strategies at which universal iron interventions can be considered safe 
should be defined.  
 Strategies (technologies and clinical protocols) to improve diagnosis and 
management of non-iron responsive anaemia in low resource settings should be 
developed.  
 The impact of non-malarial infections (e.g. diarrhoea, respiratory and skin 
infections, all common in low income countries) on iron absorption should be 
established. The effect of water, sanitation and hygiene (WASH) interventions on 
iron absorption and utilisation, iron deficiency and anaemia should be defined.  
 The lowest doses of iron in pregnancy that achieve desirable clinical outcomes 
for mother and baby should be established.  
 Functional health benefits from iron provision in young children (e.g. on cognitive 
and physical development, wellbeing) require precise definition in high quality 
trials so that evidence-based decisions can be made and risk-benefit analysis 
can be undertaken.  
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